According to the pioneering work of Thomas et al., the G protein-coupled estrogen receptor
GPER, a class A (rhodopsin-like) GPCR, interacts with estradiol (Thomas et al., 2005). This …

The discovery of epidermal growth factor receptor (EGFR) mutations has made EGFR
tyrosine kinase inhibitors (EGFR‐TKIs) a milestone in the treatment for advanced non–small …

G protein-coupled receptors (GPCRs) are among the most significant therapeutic targets
and some of them promote the growth and metastasis of cancer. Here, we show that an …

Increasing the understanding of the impact of changes in oncogenes and tumor suppressor
genes is essential for improving the management of lung cancer. Recently, we identified a …

The G-protein-coupled estrogen receptor-1 (GPER, formerly known as GPR30) has attracted
increasing interest, considering its ability to mediate estrogenic signaling in different cell …

The progesterone receptor (PR) is a key player in major physiological and pathological
responses in women, and the signaling pathways triggered following hormone binding have …

Progesterone Receptor Membrane Component 1 (PGRMC1/Sigma-2 receptor) is located on
chromosome Xq21 and encodes a haem-containing protein that interacts with epidermal …

The G protein-coupled estrogen receptor 1 (GPER1) is involved in the regulation of
physiological processes such as cellular growth and proliferation, but also in …

G-Protein Coupled Receptor (GPCR) superfamily, which comprises approximately 900
members, is the largest family of protein targets with proven therapeutic value. Although at …

More than 40% of commercialized drugs exert their action through G protein-coupled
receptors (GPCRs), indicating that the modulation of these hepta-transmembrane proteins is …